TITLE

Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality

AUTHOR(S)
Paradiso-Hardy, Fran L.; Angelo, C. Mark; Lanctot, Krista L.; Cohen, Eric A.
PUB. DATE
November 2000
SOURCE
CMAJ: Canadian Medical Association Journal;11/28/2000, Vol. 163 Issue 11, p1441
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a study on hematologic dyscrasia associated with ticlopidine therapy and evidence for causality. Background; Methods; Results; Interpretation that the study provides evidence that implicates ticlopidine as the causative factor in the various types of hematologic dyscrasia in most published case reports.
ACCESSION #
3823424

 

Related Articles

  • PERSPECTIVE: ECULIZUMAB. Boxer, Laurence // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug eculizumab which he believes has the potential to change practice.

  • PERSPECTIVE: ECULIZUMAB. Moake, Joel L. // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug eculizumab which he believes has the potential to change practice.

  • PERSPECTIVE: BRENTUXIMAB VEDOTIN. Cabanillas, Fernando // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug brentuximab vedotin which he believes has the potential to change practice.

  • PERSPECTIVE: CARFILZOMIB. Lohr, Lisa K. // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug carfilzomib which she believes has the potential to change practice.

  • Ticlopidine.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p287 

    An abstract of the article "Intraductal Papillary Mucinous Neoplasm Presenting as Hemosuccus Pancreaticus" by H. Inoue and others is presented.

  • PERSPECTIVE: PROTHROMBIN COMPLEX CONCENTRATE. Gorlin, Jed // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug prothrombin complex concentrate which he believes has the potential to change practice.

  • Neither warfarin nor heparin is needed after stenting when an antiplatelet is used.  // Modern Medicine;Jun98, Vol. 66 Issue 6, p44 

    Presents an abstract of the article `Frequency of Adverse Clinical Events in the 12 Months Following Successful Intracoronary Stent Placement in Patients Treated with Aspirin and Ticlopidine (without warfarin),' by P.B. Berger, M.R. Bell, et al from the `American Journal of Cardiology,' dated...

  • The interpretation of zinc protoporphyrin changes in lead intoxication: a case report and review of the literature. C. J. Martin; C. L. Werntz; A. M. Ducatman // Occupational Medicine;Dec2004, Vol. 54 Issue 8, p587 

    BackgroundZinc protoporphyrin (ZPP) has been used both as a screening and diagnostic test for overexposure to lead for nearly 30 years, although limitations for both purposes are recognized.MethodsWe present longitudinal findings for ZPP and whole-blood lead in a man with two episodes of acute...

  • Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII. Brenner, Benjamin; Hoffman, Ron; Balashov, Dmitriy; Shutluko, Elena; Čulić, Srđana; Nizamoutdinova, Elena // Clinical & Applied Thrombosis/Hemostasis;Oct2005, Vol. 11 Issue 4, p401 

    This paper presents an analysis of 24 cases in which recombinant factor Vila (rFVIIa) was used in the management of hemorrhage in patients with thrombocytopenia associated with hematologic malignancies. This is the largest case aggregation to date and focuses on preliminary experience in the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics